NT5E and neoplasm: In vivo studies showed that the targeted (GE11 liposomal siRNA) and non-targeted formulations (liposomal CD73 siRNA) could efficiently suppress CD73 gene expression, which significantly reduced tumor volume and increased survival rate compared to control group.